Cipla Limited — Fluticasone Exporter Profile
Indian Pharmaceutical Exporter · #1 for Fluticasone · $133.2M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Fluticasone with $133.2M in export value and 2,663 verified shipments. Cipla Limited holds a 65.6% market share in Fluticasone exports across 53 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Fluticasone Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Fluticasone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $24.5M | 526 | 28.5% |
| SOUTH AFRICA | $8.3M | 210 | 9.7% |
| CANADA | $7.5M | 207 | 8.7% |
| AUSTRALIA | $6.4M | 146 | 7.4% |
| BELGIUM | $4.9M | 593 | 5.7% |
| CHILE | $3.5M | 120 | 4.0% |
| TURKEY | $3.1M | 72 | 3.6% |
| GERMANY | $2.9M | 68 | 3.3% |
| SAUDI ARABIA | $2.5M | 55 | 2.9% |
| MOROCCO | $2.2M | 57 | 2.6% |
Cipla Limited exports Fluticasone to 57 countries. The largest destination is NETHERLANDS accounting for 28.5% of Cipla Limited's Fluticasone shipments, followed by SOUTH AFRICA (9.7%) and CANADA (8.7%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fluticasone from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MYLAN IRELAND LTD | NETHERLANDS | $16.8M | 349 |
| MYLAN IRELAND LIMITED | NETHERLANDS | $6.5M | 136 |
| APOTEX INC | CANADA | $6.4M | 182 |
| PAYAZ BIOMEDIKAL VE TIBBI CIHAZLAR | TURKEY | $3.3M | 77 |
| MEDPRO PHARMACEUTICA PTY LTD | SOUTH AFRICA | $2.9M | 65 |
| SALUTAS PHARMA GMBH | GERMANY | $2.0M | 42 |
| CIPLA MAROC | MOROCCO | $1.9M | 43 |
| LABORATORIOS RECALCINE SA.. | CHILE | $1.9M | 64 |
| MYLAN AUSTRALIA | AUSTRALIA | $1.7M | 34 |
| MEDPRO PHARMACEUTICA PTY LIMITED | SOUTH AFRICA | $1.6M | 33 |
Cipla Limited supplies Fluticasone to 192 buyers globally. The largest buyer is MYLAN IRELAND LTD (NETHERLANDS), followed by MYLAN IRELAND LIMITED (NETHERLANDS) and APOTEX INC (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fluticasone Export Value and How Much Does Cipla Limited Contribute?
India exported $145.4M worth of Fluticasone through 9,009 shipments from 239 suppliers to 123 countries, serving 664 buyers globally. Cipla Limited contributes $133.2M to this total, accounting for 65.6% of India's Fluticasone exports. Cipla Limited ships Fluticasone to 57 countries through 192 buyers.
What Is the Average Shipment Value for Cipla Limited's Fluticasone Exports?
Cipla Limited's average Fluticasone shipment value is $50.0K per consignment, based on 2,663 shipments totaling $133.2M. The largest destination is NETHERLANDS (28.5% of Cipla Limited's Fluticasone exports).
How Does Cipla Limited Compare to Other Indian Fluticasone Exporters?
Cipla Limited ranks #1 among 239 Indian Fluticasone exporters with a 65.6% market share. The top 3 exporters are CIPLA LIMITED ($133.2M), HETERO LABS LIMITED ($4.5M), ZYDUS LIFESCIENCES LIMITED ($1.7M). Cipla Limited processed 2,663 shipments to 53 destination countries.
What Fluticasone Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DYMISTA (AZELASTINE HYDROCHLORIDE 137MCG+FLUTICASONE PROPIONATE 50MCG (PER SPRAY) NASAL SUSPENSION);DYMISTA TRADE PACK -NOS | $4.4M | 100 |
| DYMISTA AZELASTINE HYDROCHLORIDE 137MCG+FLUTICASONE PROPIONATE 50MCG PER SPRAY NASAL SUSPENSION;Dymista trade pack - | $2.4M | 48 |
| DYMISTA (AZELASTINE HYDROCHLORIDE 137MCG+FLUTICASONE PROPIONATE 50MCG(PER SPRAY)NASAL SUSPENSION);Dymista trade pack - | $2.3M | 47 |
| DYMISTA (AZELASTINE HYDROCHLORIDE 137MCG+FLUTICASONE PROPIONATE 50MCG (PER SPRAY) NASAL SUSPENSION);DYMISTA TRADE PACK - | $2.3M | 46 |
| DYMISTA (AZELASTINE HYDROCHLORIDE 137MCG+FLUTICASONE PROPIONATE 50MCG (PER SPRAY) NASAL SUSPENSION);Dymista trade pack - | $2.2M | 44 |
| APO-FLUTICASONE HFA 250MCG/MD(WITH POUCH | $1.7M | 53 |
| DYMISTA AZELASTINE HCL 137MCG FLUTICASONE PROPIONATE 50MCG PER SPRAY NASAL SUSPENSION 17ml 120spray P S 1X120 MD | $1.6M | 32 |
| FLOMIST NASAL SPRAY (FLUTICASONE PROPION | $1.4M | 38 |
| FLOHALE 250 HFA INHALER FLUTICASONE PRO | $856.6K | 24 |
| FLUTICASONE PROPIONATE 250 MCG AND SALME | $800.5K | 17 |
Cipla Limited exports 903 distinct Fluticasone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DYMISTA (AZELASTINE HYDROCHLORIDE 137MCG+FLUTICASONE PROPION with 100 shipments worth $4.4M. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Fluticasone to Key Markets
What Cipla Limited must comply with to export Fluticasone to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Cipla Limited Compare to Nearest Fluticasone Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $133.2M | 2,663 | 53 | $50.0K |
| 2 | HETERO LABS LIMITED | $4.5M | 112 | 4 | $40.5K |
| 4 | ZYDUS LIFESCIENCES LIMITED | $1.7M | 93 | 8 | $17.9K |
Cipla Limited ranks #1 among 239 Indian Fluticasone exporters. Average shipment value of $50.0K compared to the market average of $608.3K. The closest competitors by value are HETERO LABS LIMITED and ZYDUS LIFESCIENCES LIMITED.
Which Indian Ports Ship Fluticasone Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 2,008 | 22.3% |
| DELHI AIR | 1,273 | 14.1% |
| DELHI AIR CARGO ACC (INDEL4) | 1,244 | 13.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 982 | 10.9% |
| NHAVA SHEVA SEA (INNSA1) | 473 | 5.3% |
| Bombay Air | 426 | 4.7% |
| JNPT/ NHAVA SHEVA SEA | 342 | 3.8% |
| Delhi Air | 296 | 3.3% |
What Other Respiratory Products Does Cipla Limited Export?
Cipla Limited also exports these respiratory products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Cipla Limited's Fluticasone Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Fluticasone, top products include Amlodipine, Salbutamol, Telmisartan, Salmeterol, Budesonide. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fluticasone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fluticasone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 2,663 individual customs records matching Cipla Limited exporting Fluticasone, covering 903 formulations to 57 countries via 192 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 123+ countries, 664+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fluticasone Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Fluticasone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Fluticasone Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fluticasone. For current shipment-level data, contact TransData Nexus.